Orphengesic Forte has received a decision date of August 14, 2019.
Orphengesic Forte has received a decision date of August 14, 2019.
Though most forms of marijuana are highly regulated, CBD products are readily available across the country. What does this mean for healthcare?
In a call for public comment, the FDA believes that reducing excess opioid supplies can lower opioid misuse, abuse, and overdose.
The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.
New changes to REMS safety programs will require stronger treatment documentation and oversight.
Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.
Can special implants in the brain override paralysis? The FDA believes one day they could.
The FDA created special drug labels to clear a development hurdle and encourage manufacturers.
